Pirenoxine Sodium Eye Drops 0.8mg

• Customization: Available
• Quality Standard: Bp, USP
• Ctd Dossier: Ready
• Model NO.: eye drops
• Trademark: Sinolead
• Origin: China
• Production Capacity: 100, 000, 000 Per Year

Product Description

Product Description

Generic Name	Pirenoxine Sodium Eye drops 0.8mg
Strength	0.8mg
Packing	1 tube/box
Origin	China

Value-added services:
 Packaging design by our team
 Registration service by our team
 Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Product name:
Pirenoxine Sodium Eye drops 0.8mg

Character:
The tablets of this product are orange-red tablets, and the special solvent is colorless and transparent liquid. After the tablet is dissolved into a special solvent, the inside will appear light yellow or orange yellow liquid.

Indications:
The main treatment is early senile cataract, mild diabetic cataract or complicated cataract.

Matters needing attention:
1. Put 1 tablet into 1 bottle of solvent before use, and wait until the medicine is completely dissolved before use. After the tablet is dissolved in the solvent, it should be used continuously and used up within 20 days.
2. Patients with cataracts caused by diabetes should be treated with this product combined with other methods under the guidance of doctors.
3. Do not make the mouth of the tube contact with hands and eyes during eye drops to avoid contaminating the eye drops in the bottle.
4. This product should be kept away from light; Tighten the cap after use to prevent contamination.
5. This product is not allowed for allergic people, and should be used with caution for allergic people.
6. Do not use when the character of this product changes.
7. Keep this product out of reach of children.
8. If you are using other drugs, please consult your doctor or pharmacist before using this product.

Pharmacology and toxicology:
Studies have shown that one of the reasons for cataract formation is that soluble proteins in the lens are gradually changed into insoluble proteins by the action of quinones.
Quinones are formed by the abnormal metabolism of tryptophan, an important functional amino acid in the body.
The effect of quinones on the soluble protein of lens can be competitively inhibited by pyranoxine sodium.
In addition, piroxine sodium can also fight free radical damage to the lens caused by cataracts.
Therefore, this product has a certain inhibitory effect on the development of cataracts.
Animal experiments have shown that piroxine sodium can reduce the incidence of posterior capsule opacity after extracapsular cataract extraction.

Storage:
Keep out of light and tightly sealed.